Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025

Dogwood Therapeutics, Inc.

2025-Q2 EPS reported -$9.51 vs consensus -$1.94 ▼ miss (-390.7%)

Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.
R&D expenses $2.5M (up from $0.3M) driven by clinical trial costs; G&A $1.3M (up from $0.7M).
Net loss $3.8M ($1.99 per share) vs $1.0M ($1.15) in Q2 2024; no revenue reported.
Cash $13.4M expected to fund operations through Q1 2026; Halneuron fast-tracked by FDA.
IMC-1 (fibromyalgia) ready for Phase 3; IMC-2 (Long-COVID) paused due to government funding uncertainty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.